A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign

A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign
08/24/2016 02:16 pm ET Andrew B. Palumbo

In thirty seconds, a rash of angry red hives had covered her body. She was uncomfortable but unaware of what was happening. There was a look of extreme fear in her eyes. Another minute passed and her airway began to close as her body fought the allergic reaction. I quickly laid my daughter down and plunged an EpiPen into her left thigh as my wife called 911.

This is the reality for the fifteen million people living with food allergies and their families. Cecelia has life threatening food allergies to milk, eggs, peanuts, tree nuts, shellfish, garlic, sesame, sunflower, coconut, and kiwi. She is two years old.

The EpiPen’s only legitimate U.S. competitor, Sanofi’s Auvi-Q, was voluntarily recalled nationwide in October 2015 after dangerous issues of inaccurate dosage delivery arose that could include a failure to administer the life-saving epinephrine. Immediately, millions of families with life threatening allergies turned to Mylan to secure EpiPens.

The result was a de facto monopoly for Mylan.

http://www.huffingtonpost.com/entry/a-call-for-mylan-ceo-heather-bresch-to-reduce-epipen_us_57bddc84e4b06384eb3de642?section=&